{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:03:59Z","timestamp":1779235439686,"version":"3.51.4"},"reference-count":76,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Fragile X syndrome (FXS) is the leading known cause of inherited intellectual disability and autism spectrum disorder. It is caused by a mutation of the fragile X mental retardation 1 (FMR1) gene, resulting in a deficit of fragile X mental retardation protein (FMRP). The clinical presentation of FXS is variable, and is typically associated with developmental delays, intellectual disability, a wide range of behavioral issues, and certain identifying physical features. Over the past 25 years, researchers have worked to understand the complex relationship between FMRP deficiency and the symptoms of FXS and, in the process, have identified several potential targeted therapeutics, some of which have been tested in clinical trials. Whereas most of the basic research to date has been led by experts at academic institutions, the pharmaceutical industry is becoming increasingly involved with not only the scientific community, but also with patient advocacy organizations, as more promising pharmacological agents are moving into the clinical stages of development. The objective of this review is to provide an industry perspective on the ongoing development of mechanism-based treatments for FXS, including identification of challenges and recommendations for future clinical trials.<\/jats:p>","DOI":"10.3390\/brainsci8120214","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T12:22:00Z","timestamp":1544012520000},"page":"214","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective"],"prefix":"10.3390","volume":"8","author":[{"given":"Anna W.","family":"Lee","sequence":"first","affiliation":[{"name":"Ovid Therapeutics Inc., New York, NY 10036, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Ventola","sequence":"additional","affiliation":[{"name":"Child Study Center, Yale University, New Haven, CT 06520, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-5134","authenticated-orcid":false,"given":"Dejan","family":"Budimirovic","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Behavioral Sciences, Kennedy Krieger Institute and Child Psychiatry, Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Berry-Kravis","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics, Neurological Sciences, Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannie","family":"Visootsak","sequence":"additional","affiliation":[{"name":"Ovid Therapeutics Inc., New York, NY 10036, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1542\/peds.2016-1159B","article-title":"The future of fragile X syndrome: CDC Stakeholder Meeting summary","volume":"139","author":"Riley","year":"2017","journal-title":"Pediatrics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ridd.2014.01.032","article-title":"Psychiatric symptoms in boys with fragile X syndrome: A comparison with nonsyndromic autism spectrum disorder","volume":"35","author":"Thurman","year":"2014","journal-title":"Res. Dev. Disabil."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1542\/peds.2016-1159F","article-title":"Autism Spectrum Disorder in fragile X syndrome: Cooccurring conditions and current treatment","volume":"139","author":"Kaufmann","year":"2017","journal-title":"Pediatrics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/13854046.2016.1184652","article-title":"The fragile X mental retardation 1 gene (FMR1): Historical perspective, phenotypes, mechanism, pathology, and epidemiology","volume":"30","author":"Grigsby","year":"2016","journal-title":"Clin. Neuropsychol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2018.04.008","article-title":"Aberrant RNA translation in fragile X syndrome: From FMRP mechanisms to emerging therapeutic strategies","volume":"1693","author":"Banerjee","year":"2018","journal-title":"Brain Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.12688\/f1000research.11885.1","article-title":"Fragile X syndrome and fragile X-associated disorders","volume":"6","author":"Rajaratnam","year":"2017","journal-title":"F1000Research"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/ajmg.a.32261","article-title":"MosaicFMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: A case report and review of the literature","volume":"146A","author":"Coffee","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ejhg.2008.61","article-title":"Fragile X syndrome","volume":"16","author":"Garber","year":"2008","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1542\/peds.2013-4301","article-title":"Fragile X syndrome: A review of associated medical problems","volume":"134","author":"Kidd","year":"2014","journal-title":"Pediatrics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17065","DOI":"10.1038\/nrdp.2017.65","article-title":"Fragile X syndrome","volume":"3","author":"Hagerman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/17518423.2012.704414","article-title":"Parental reports on early language and motor milestones in fragile X syndrome with and without autism spectrum disorders","volume":"16","author":"Hinton","year":"2013","journal-title":"Dev. Neurorehabil."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11689-010-9067-y","article-title":"Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization","volume":"3","author":"Cordeiro","year":"2011","journal-title":"J. Neurodev. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kaufmann, W.E., Capone, G., Clarke, M., and Budimirovic, D.B. (2008). Autism in genetic intellectual disability: Insights into idiopathic autism. Autism: Current Theories and Evidence, The Humana Press Inc.","DOI":"10.1007\/978-1-60327-489-0_4"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1007\/s10803-011-1422-7","article-title":"Daily health symptoms of mothers of adolescents and adults with fragile X syndrome and mothers of adolescents and adults with autism spectrum disorder","volume":"42","author":"Smith","year":"2012","journal-title":"J. Autism Dev. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1352\/0895-8017(2004)109<237:PWACIM>2.0.CO;2","article-title":"Psychological well-being and coping in mothers of youths with autism, down syndrome, or fragile X syndrome","volume":"109","author":"Abbeduto","year":"2004","journal-title":"Am. J. Ment. Retard."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/sleep\/33.5.679","article-title":"Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey","volume":"33","author":"Kronk","year":"2010","journal-title":"Sleep"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00415-011-6161-3","article-title":"Fragile X-associated disorders: A clinical overview","volume":"259","author":"Gallagher","year":"2012","journal-title":"J. Neurol."},{"key":"ref_18","first-page":"280","article-title":"Drug development for neurodevelopmental disorders: Lessons learned from fragile X syndrome","volume":"17","author":"Lindemann","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1542\/peds.89.3.395","article-title":"Girls with fragile X syndrome: Physical and neurocognitive status and outcome","volume":"89","author":"Hagerman","year":"1992","journal-title":"Pediatrics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/(SICI)1096-8628(19960809)64:2<350::AID-AJMG23>3.0.CO;2-D","article-title":"A controlled study of longitudinal IQ changes in females and males with fragile X syndrome","volume":"64","author":"Cheema","year":"1996","journal-title":"Am. J. Med. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1866-1955-6-16","article-title":"Improving IQ measurement in intellectual disabilities using true deviation from population norms","volume":"6","author":"Sansone","year":"2014","journal-title":"J. Neurodev. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1542\/peds.2016-1159C","article-title":"Public health literature review of fragile X syndrome","volume":"139","author":"Raspa","year":"2017","journal-title":"Pediatrics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1542\/peds.2008-0317","article-title":"Advances in the treatment of fragile X syndrome","volume":"123","author":"Hagerman","year":"2009","journal-title":"Pediatrics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5582\/irdr.2016.01048","article-title":"Fragile X syndrome: A review of clinical management","volume":"5","author":"Lozano","year":"2016","journal-title":"Intractable Rare Dis. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ng0893-335","article-title":"The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation","volume":"4","author":"Devys","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/hmg\/6.8.1315","article-title":"Differential expression of FMR1, FXR1 and FXR2 proteins in human brain and testis","volume":"6","author":"Tamanini","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/excr.2000.4932","article-title":"Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse","volume":"258","author":"Bakker","year":"2000","journal-title":"Exp. Cell Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s11689-017-9186-9","article-title":"Fragile X targeted pharmacotherapy: Lessons learned and future directions","volume":"9","author":"Erickson","year":"2017","journal-title":"J. Neurodev. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biocel.2014.05.004","article-title":"New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model","volume":"53","author":"Maldonado","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neuroscience.2012.03.049","article-title":"The trouble with spines in fragile X syndrome: Density, maturity and plasticity","volume":"251","author":"He","year":"2013","journal-title":"Neuroscience"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5937\/engrami1504005B","article-title":"Neurobehavioral features and targeted treatments in fragile X syndrome: Current insights and future directions","volume":"37","author":"Budimirovic","year":"2015","journal-title":"Engrami"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","article-title":"The mGluR theory of fragile X mental retardation","volume":"27","author":"Bear","year":"2004","journal-title":"Trends Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000329420","article-title":"Fragile X syndrome: The GABAergic system and circuit dysfunction","volume":"33","author":"Paluszkiewicz","year":"2011","journal-title":"Dev. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s11689-017-9193-x","article-title":"Updated report on tools to measure outcomes of clinical trials in fragile X syndrome","volume":"9","author":"Budimirovic","year":"2017","journal-title":"J. Neruodev. Disord."},{"key":"ref_35","unstructured":"(2018, October 11). US National Library of Medicine Fragile X Syndrome, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14653","DOI":"10.1038\/s41598-017-15028-x","article-title":"Multiple behavior phenotypes of the fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D)","volume":"7","author":"Gurney","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kelley, D.J., Davidson, R.J., Elliott, J.L., Lahvis, G.P., Yin, J.C.P., and Bhattacharyya, A. (2007). The cyclic AMP cascade is altered in the fragile X nervous system. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000931"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.410310105","article-title":"Cyclic AMP metabolism in fragile X syndrome","volume":"31","author":"Huttenlocher","year":"1992","journal-title":"Ann. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajmg.1320450120","article-title":"Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome","volume":"45","author":"Sklena","year":"1993","journal-title":"Am. J. Med. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1523\/JNEUROSCI.1356-12.2015","article-title":"PDE-4 Inhibition rescues aberrant synaptic plasticity in drosophila and mouse models of fragile X syndrome","volume":"35","author":"Choi","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"13111","DOI":"10.1523\/JNEUROSCI.1347-12.2012","article-title":"Learning and memory deficits consequent to reduction of the fragile X mental retardation protein result from metabotropic glutamate receptor-mediated inhibition of cAMP signaling in drosophila","volume":"32","author":"Kanellopoulos","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41386-018-0178-6","article-title":"Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice","volume":"43","author":"Zhang","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1152\/jn.00450.2011","article-title":"Molecular basis for the high THIP\/gaboxadol sensitivity of extrasynaptic GABA A receptors","volume":"106","author":"Meera","year":"2011","journal-title":"J. Neurophysiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1523\/JNEUROSCI.2679-05.2005","article-title":"Extrasynaptic GABAA Receptors of Thalamocortical Neurons: A Molecular Target for Hypnotics","volume":"25","author":"Belelli","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.bjp.0704795","article-title":"Pharmacological characterization of a novel cell line expressing human a4b3d GABAA receptors","volume":"136","author":"Brown","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1042\/bst0320553","article-title":"Differentiating the role of \u03b3-aminobutyric acid type A (GABAA) receptor subtypes","volume":"32","author":"Wafford","year":"2004","journal-title":"Biochem. Soc. Trans."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.brainres.2008.11.075","article-title":"Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor\/ataxia syndrome (FXTAS)","volume":"1253","author":"Heulens","year":"2009","journal-title":"Brain Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9929","DOI":"10.1523\/JNEUROSCI.1714-10.2010","article-title":"Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome","volume":"30","author":"Paluszkiewicz","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000329424","article-title":"Amygdala regulation of fear and emotionality in fragile X syndrome","volume":"33","author":"Corbin","year":"2011","journal-title":"Dev. Neurosci."},{"key":"ref_51","first-page":"323","article-title":"Gaboxadol normalizes behavioral abnormalities in a mouse model of fragile X syndrome (P1.323)","volume":"19","author":"Cogram","year":"2018","journal-title":"Neurology"},{"key":"ref_52","unstructured":"Heussler, H.S., Cohen, J., Silove, N., Tich, N., O\u2019Neill, C., and Bonn-Miller, M.O. (2018). Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS), Zynerba Pharmaceuticals."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tips.2016.12.004","article-title":"Cannabidiol claims and misconceptions","volume":"38","author":"Russo","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u03949-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review: Mechanistic studies (in vivo and ex vivo) of CBD and THCV","volume":"172","author":"McPartland","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","article-title":"Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects: Phytocannabinoid-terpenoid entourage effects","volume":"163","author":"Russo","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/can.2015.0004","article-title":"Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid","volume":"1","author":"Merrick","year":"2016","journal-title":"Cannabis Cannabiniod Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1523\/JNEUROSCI.0795-10.2010","article-title":"Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome","volume":"30","author":"Zhang","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nm.3127","article-title":"Targeting the endocannabinoid system in the treatment of fragile X syndrome","volume":"19","author":"Guegan","year":"2013","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/npp.2010.19","article-title":"Abnormal mGlu 5 receptor\/endocannabinoid coupling in mice lacking FMRP and BC1 RNA","volume":"35","author":"Maccarrone","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/ncomms2045","article-title":"Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome","volume":"3","author":"Jung","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbr.2015.05.003","article-title":"Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome","volume":"291","author":"Qin","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_62","unstructured":"Bonn-Miller, M., Sebree, T., O\u2019Neill, C., and Messenheimer, J. (2016). Neuropsychological Effects of ZYN002 (Synthetic Cannabidiol) Transdermal Gel in Healthy Subjects and Patients with Epilepsy: Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies, Zynerba Pharmaceuticals."},{"key":"ref_63","unstructured":"Sebree, T., O\u2019Neill, C., Messenheimer, J., and Gutterman, D. (2016). Safety and Tolerability of ZYN002 (Synthetic Cannabidiol) Transdermal Permeation-Enhanced Gel in Healthy Subjects and Patients with Epilepsy: Three Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies, Zynerba Pharmaceuticals."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s13311-015-0355-9","article-title":"Therapeutic strategies in fragile X syndrome: From bench to bedside and back","volume":"12","author":"Gross","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/jmg.2008.063701","article-title":"A pilot open label, single dose trial of fenobam in adults with fragile X syndrome","volume":"46","author":"Hessl","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"64ra1","DOI":"10.1126\/scitranslmed.3001708","article-title":"Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056","volume":"3","author":"Jacquemont","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_67","first-page":"321ra5","article-title":"Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials","volume":"8","author":"Hagerman","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/tnsci-2017-0002","article-title":"Fragile X syndrome: Lessons learned from the most translated neurodevelopmental disorder in clinical trials","volume":"8","author":"Duy","year":"2017","journal-title":"Transl. Neurosci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Leclercq, M., and Zimmermann, P. (2004). A test battery for attentional performance. Applied Neuropsychology of Attention Theory, Diagnosis and Rehabilatation, Psychology Press.","DOI":"10.4324\/9780203307014-12"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1866-1955-4-2","article-title":"Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS)","volume":"4","author":"Knox","year":"2012","journal-title":"J. Neurodev. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/DBP.0b013e31828742fc","article-title":"Development of an expressive language sampling procedure in fragile X syndrome: A pilot study","volume":"34","author":"Doll","year":"2013","journal-title":"J. Dev. Behav. Pediatr."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1212\/WNL.0b013e3182872ded","article-title":"Cognition assessment using the NIH Toolbox","volume":"80","author":"Weintraub","year":"2013","journal-title":"Neurology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s11689-016-9167-4","article-title":"The NIH Toolbox Cognitive Battery for intellectual disabilities: Three preliminary studies and future directions","volume":"8","author":"Hessl","year":"2016","journal-title":"J. Neurodev. Disord."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.dhjo.2012.08.005","article-title":"Evaluation of an activities of daily living scale for adolescents and adults with developmental disabilities","volume":"6","author":"Maenner","year":"2013","journal-title":"Disabil. Health J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.ridd.2014.06.012","article-title":"Maternal well-being and child behavior in families with fragile X syndrome","volume":"35","author":"Hauser","year":"2014","journal-title":"Res. Dev. Disabil."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/npp.2011.137","article-title":"Therapeutic strategies in fragile X syndrome: Dysregulated mGluR signaling and beyond","volume":"37","author":"Gross","year":"2012","journal-title":"Neuropsychpharmacology"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/8\/12\/214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:31:14Z","timestamp":1760196674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/8\/12\/214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,5]]},"references-count":76,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["brainsci8120214"],"URL":"https:\/\/doi.org\/10.3390\/brainsci8120214","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,5]]}}}